Kenvue (NYSE:KVUE) Price Target Cut to $23.00 by Analysts at UBS Group

Kenvue (NYSE:KVUE) had its price target lowered by UBS Group from $24.00 to $23.00 in a report issued on Thursday,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other research firms also recently weighed in on KVUE. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Barclays upgraded Kenvue to a “hold” rating in a research report on Thursday, December 12th. JPMorgan Chase & Co. boosted their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, Bank of America raised their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $23.27.

Kenvue Stock Up 1.7 %

Kenvue stock opened at $21.21 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $40.66 billion, a PE ratio of 38.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The business has a 50 day simple moving average of $22.47 and a 200-day simple moving average of $21.64. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm’s revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.31 EPS. On average, analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Leo Wealth LLC increased its position in Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after purchasing an additional 481 shares during the last quarter. Alerus Financial NA increased its holdings in shares of Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after buying an additional 491 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its position in shares of Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after buying an additional 492 shares during the period. Kiley Juergens Wealth Management LLC lifted its holdings in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after acquiring an additional 500 shares during the last quarter. Finally, Wolff Wiese Magana LLC grew its position in Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.